Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

Adar Poonawalla backed Serum Insitute has applied for EU authorities nod for Covishield&nbsp;to ensure it is eligible for travellers to get the 'Green Pass' or vaccine passport for EU.&nbsp;&nbsp;The application has come at a time when beneficiaries of Covishield were termed ineligible for travelling to the European UnionReports indicate that Serum expects the vaccine to be cleared soon for emergency use authorisation with the EMA.&nbsp;COVID-19 vaccines developed by AstraZeneca, Pfizer, Moderna and Johnson and Johnson have received EMA's emergency use authorisation. Those administered these vaccines are eligible for the EU's digital certificate or Green Pass.&nbsp;

EU Green Pass: Serum applies for EU approval for Covishield

Adar Poonawalla wants to ensure that you can travel to Europe!&nbsp;

Poonawalla's push for green pass

<ul>
<li>Serum applies for EU drug regulator nod for Covishield&nbsp;</li>
<li>Covishield&nbsp;not eligibile for EU green pass without EMA&nbsp;nod</li>
<li>AstraZeneca&nbsp;manuactured&nbsp;vaccine has green pass nod, Covishield&nbsp;awaiting approval</li>
<li>Serum expects approval from EMA&nbsp;for&nbsp;Covishield&nbsp;soon</li>
<li>AstraZeneca, Pfizer, Moderna, J&amp;J jabs have nod from EU for Green Pass</li>
</ul>

Move follows reports that&nbsp;EU&rsquo;s vaccine passport recognizes Astra-Zeneca&rsquo;s Vaxzevria but not Covishield.&nbsp;

Adar Poonawalla backed Serum Insitute has applied for EU authorities nod for Covishield&nbsp;to ensure it is eligible for travellers to get the 'Green Pass' or vaccine passport for EU.&nbsp;&nbsp;The application has come at a time when beneficiaries of Covishield were termed ineligible for travelling to the European Union Reports indicate that Serum expects the vaccine to be cleared soon for emergency use authorisation with the EMA.&nbsp; COVID-19 vaccines developed by AstraZeneca, Pfizer, Moderna and Johnson and Johnson have received EMA's emergency use authorisation. Those administered these vaccines are eligible for the EU's digital certificate or Green Pass.&nbsp;

Serum's manufacturing site will have to assessed for Covishield to get Green Pass appoval by EMA&nbsp;as per reports.&nbsp;The EMA&nbsp;said that approval for&nbsp;AstraZenca&nbsp;manufatcured&nbsp;Vaxzevria&nbsp;does not mean nod for Covishiel. In an email as reported by News18 EMA&nbsp;stated&nbsp;&ldquo;Even tiny differences in the manufacturing conditions can result in differences in the final product, and EU law therefore requires the manufacturing sites and production process to be assessed and approved as part of the authorisation process.&rdquo;However, the EMA&nbsp;also has clarified that the authority to issue or approve a green pass for travellers rests with the EU nation members but is linked with linked to EU marketing authorisation for vaccines which currently Serum's Covishield&nbsp;does not have.&nbsp;

Green Pass nod for AstraZenca does not mean the same for Serum: EMA

Green Pass route not so easy,&nbsp;EMA to assess Serum's manufacturing site&nbsp;

Serum pushes for Green Pass for Covishield 

Serum's manufacturing site will have to assessed for Covishield to get Green Pass approval by EMA&nbsp;as per reports.&nbsp;
The EMA&nbsp;said that approval for&nbsp;AstraZenca&nbsp;manufatcured&nbsp;Vaxzevria&nbsp;does not mean nod for Covishiel. In an email as reported by News18 EMA&nbsp;stated&nbsp;&ldquo;Even tiny differences in the manufacturing conditions can result in differences in the final product, and EU law therefore requires the manufacturing sites and production process to be assessed and approved as part of the authorisation process.&rdquo;
However, the EMA&nbsp;also has clarified that the authority to issue or approve a green pass for travellers rests with the EU nation members but is linked with linked to EU marketing authorisation for vaccines which currently Serum's Covishield&nbsp;does not have.&nbsp;

EMA to assess Serum's manufacturing site before giving approval needed for Green Pass.

Serum's manufacturing site will have to assessed for Covishield to get Green Pass approval by EMA&nbsp;as per reports.&nbsp; The EMA&nbsp;said that approval for&nbsp;AstraZenca&nbsp;manufatcured&nbsp;Vaxzevria&nbsp;does not mean nod for Covishield. In an email as reported by News18 EMA&nbsp;stated&nbsp;&ldquo;Even tiny differences in the manufacturing conditions can result in differences in the final product, and EU law therefore requires the manufacturing sites and production process to be assessed and approved as part of the authorisation process.&rdquo; However, the EMA&nbsp;also has clarified that the authority to issue or approve a green pass for travellers rests with the EU nation members but is linked with linked to EU marketing authorisation for vaccines which currently Serum's Covishield&nbsp;does not have.&nbsp;

Adar Poonawalla, CEO Serum Institute of India announced that the company has started manufacturing the first batch of Covid&nbsp;vaccine&nbsp;Covovax (developed by Novavax) . In a tweet Poonawalla&nbsp;said&nbsp;"Excited to witness the first batch of Covovax (developed by @Novavax) being manufactured this week at our facility in Pune. The vaccine has great potential to protect our future generations below the age of 18. Trials are ongoing."Serum&nbsp;has partnered with US bcompany Novavax to conduct bridge trials on the jab and manufacture the vaccine. The govt&nbsp;expects the vaccine to be available&nbsp;from August to December though has not signed any supply contract with SII&nbsp;for the same yet.&nbsp;

Poonawalla says Serum has begun production of Novavax Covid vaccine 

Serum Institute of India begins manufacturing of Novavax&nbsp;Covid-19&nbsp;vaccine at Pune facility.&nbsp;

<ul>
<li>Serum Institute begins production of Novavax covid vaccine</li>
<li>Poonawalla: Excited to witness first batch of Covovax</li>
<li>Poonawalla:'Vaccine has great potential to protect those below 18'</li>
<li>Govt&nbsp;has not signed any supply contract with SII&nbsp;for Novovax&nbsp;yet</li>
<li>Novavax&nbsp;claims to have&nbsp;90.4 % efficacy against Covid-19</li>
</ul>

Adar Poonawalla, CEO Serum Institute of India announced that the company has started manufacturing the first batch of Novovax's&nbsp;Covid&nbsp;vaccine&nbsp;Covovax&nbsp;. In a tweet Poonawalla&nbsp;said&nbsp;"Excited to witness the first batch of Covovax&nbsp;being manufactured this week at our facility in Pune. The vaccine has great potential to protect our future generations below the age of 18. Trials are ongoing." Serum&nbsp;has partnered with US biotech company Novavax to conduct bridge trials on the jab and manufacture the vaccine. The govt&nbsp;expects the vaccine to be available&nbsp;from August to December though has not signed any supply contract with SII&nbsp;for the same yet.&nbsp;

Vaccine manufacturers&nbsp;Serum and Bharat&nbsp;Biotech&nbsp;told the central govt that they are looking to&nbsp;ramp up production to 10 crore and 7.8 crore doses respectively by August.&nbsp;Amid a severe vaccine shortage across states , Union Health Ministry and the office of Drugs Controller General of India had sought from both the firms their production plan for June, July, August and September, sources told&nbsp;PTI.&nbsp;

Serum Institute, Bharat Biotech to increase vaccine production by August

Amid a severe shortage the govt sought a production plan from the vaccine manufacturers.&nbsp;

<ul>
<li>Serum, Bharat&nbsp;Bio submit production plans to govt</li>
<li>Serum, Bharat&nbsp;Biotech&nbsp;look to ramp up capacity by August</li>
<li>Serum to produce 10 cr doses by August&nbsp;</li>
<li>Bharat&nbsp;Biotech&nbsp;to produce 7.8 cr doses by August&nbsp;</li>
<li>Govt had sought production plan from vaccine manufacturers&nbsp;</li>
</ul>

Vaccine manufacturers&nbsp;Serum and Bharat&nbsp;Biotech&nbsp;told the central govt that they are looking to&nbsp;ramp up production to 10 crore and 7.8 crore doses respectively by August.&nbsp; Amid a severe vaccine shortage across states , Union Health Ministry and the office of Drugs Controller General of India had sought from both the firms their production plan for June, July, August and September, sources told&nbsp;PTI.&nbsp;

Just two days after Bangaldesh&nbsp;gave emergency nod to Russia's covid&nbsp;vaccine Sputnik V, the govt has now allowed&nbsp;emergency use of China's covid&nbsp;vaccine&nbsp;Sinopharm. The move comes as export obligation for India made covid&nbsp;vaccine was not fulfilled.&nbsp;
Bangladesh purchased 30 million doses of India based Serum produced Covishield&nbsp;&nbsp;and under an agreement, received seven million doses in two consignments until February while the third consignment, which was expected in March, is yet to reach.Bangladesh has reported total fatalities of 11,393.&nbsp;

Bangladesh gives emergency nod to Chinese vaccine as Serum fails to deliver doses

Just two days after Bangaldesh&nbsp;gave emergency nod to Russia's covid&nbsp;vaccine Sputnik V, the govt has now allowed&nbsp;emergency use of China's covid&nbsp;vaccine&nbsp;Sinopharm. The move comes as export obligation for India made covid&nbsp;vaccine was not fulfilled.&nbsp;
Bangladesh purchased 30 million doses of India based Serum produced Covishield&nbsp;&nbsp;and under an agreement, received seven million doses in two consignments until February while the third consignment, which was expected in March, is yet to reach. Bangladesh has reported total fatalities of 11,393.&nbsp;

<ul>
<li>Bangladesh gives emergency nod to Chinese vaccine&nbsp;</li>
<li>Nod to Sinopharm&nbsp;as Serum vaccines not delivered&nbsp;</li>
<li>Bangladesh govt also cleared&nbsp;Sputnik for use</li>
<li>Bangladesh bought 30 million doses of SII vaccine, received&nbsp;7mn&nbsp;</li>
</ul>

Just two days after Bangaldesh&nbsp;gave emergency nod to Russia's covid&nbsp;vaccine Sputnik V, the govt has now allowed&nbsp;emergency use of China's covid&nbsp;vaccine&nbsp;Sinopharm. The move comes as export obligation for India made covid&nbsp;vaccine was not fulfilled.&nbsp;
Bangladesh purchased 30 million doses of India based Serum produced Covishield&nbsp;&nbsp;and under an agreement, received seven million doses in two consignments until February while the third consignment, which was expected in March, is yet to reach. Bangladesh has reported total fatalities of 11,393.&nbsp;

Reports indicate that the Maharashtra&nbsp;government has written to vaccine manufacturers Serum and Bharat&nbsp;Biotech&nbsp;to give clarity on availability and&nbsp;supply of vaccines over the next months. Uddhav&nbsp;Thackeray led state govt is also seeking final clarity on pricing of the doses. The state would need 12 crore&nbsp;vaccines to cover the eligible population from May 1.&nbsp;Maharashtra on Monday set a record by vaccinating five lakh people for COVID-19 in a single day, the highest ever by any State in the country.

Maharashtra Govt writes to vaccine producers Serum & Bharat Biotech, seeks clarity for 6 month supply 

As the Uddhav&nbsp;Thackeray govt prepares for mass vaccination from May 1, the state govt has sought clarity on supply from Covishield and Covaxin&nbsp;manufacturers.&nbsp;

Maharashtra to vaccine makers, give clarity on supply

Reports indicate that the Maharashtra&nbsp;government has written to vaccine manufacturers Serum and Bharat&nbsp;Biotech&nbsp;to give clarity on availability and&nbsp;supply of vaccines over the next 6 months. Uddhav&nbsp;Thackeray led state govt has also sought final clarity on pricing of the doses. The state would need 12 crore&nbsp;vaccines to cover the eligible population from May 1.&nbsp;Maharashtra on Monday set a record by vaccinating five lakh people for COVID-19 in a single day, the highest ever by any State in the country.

In a big breather for the nation and Serum Institute the United States government has finally agreed to lift the export ban and immediately provide raw material urgently required for manufacturing&nbsp;Covishield vaccine.&nbsp;The statement from Biden&nbsp;govt comes after a phone conversation between US National Security Advisor Jake Sullivan and National Security Advisor Ajit Doval.&nbsp;The White House in it's release also stated that they are pursuing options to provide oxygen generation and related supplies on an urgent basis.Adar Poonawalla&nbsp;had made repeated requests on public forums to the United States government to release raw materials needed to make Covid-19 vaccine.

US lifts export ban, agrees to send raw material 'urgently required' for Covishield

In a big breather for the nation and Serum Institute the United States government has finally agreed to lift the export ban and immediately provide raw material urgently required for manufacturing&nbsp;Covishield vaccine.&nbsp;

US agrees to send raw material for Covishield, ends exports ban

US lifts export ban on&nbsp;Covishield vaccine raw material
US decision after talks between the nations&nbsp;&nbsp;
US also to provide oxygen generation, related supplies&nbsp;
US had banned export of&nbsp;raw materials needed to make vaccine&nbsp;
&nbsp;

In a big breather for the nation and Serum Institute the United States government has finally agreed to lift the export ban and immediately provide raw material urgently required for manufacturing&nbsp;Covishield vaccine.&nbsp; The statement from Biden&nbsp;govt comes after a phone conversation between US National Security Advisor Jake Sullivan and National Security Advisor Ajit Doval.&nbsp; The White House in it's release also stated that they are pursuing options to provide oxygen generation and related supplies on an urgent basis. Adar Poonawalla&nbsp;had made repeated requests on public forums to the United States government to release raw materials needed to make Covid-19 vaccine.

India's largest vaccine manufacturer Serum comes forward to clarify as it faces backlash on India paying the highest price for the Covishield vaccines.Serum in a statement released on Saturday said, that the comparison of global prices to Indian prices was inaccurate as the global vaccines were procured on advance funding.&nbsp;Serum also reassured&nbsp; that only a limited portion of it's total supply will be sold at Rs 600/dose as majority will be supplied at the govt procurement price of Rs 400/dose which as it states is much lower than any covid&nbsp;treatment plan in any health centre.&nbsp;Adar Ponawalla&nbsp;urged the market to opened up further for other vaccines from around the world to increase the vaccination pace.&nbsp;

Serum says vaccination cost in India as low as possible, can't be compared 

Gloval&nbsp;prices of vaccine were low due to advance funding; Price in India is&nbsp;much lower than treatments says Serum Chief Adar Poonawalla,

<ul>
<li>Serum faces backlash on pricing of covishield&nbsp;vaccine at Rs 600/dose</li>
<li>Serum: Can not compare pricing to cost of dosage given with advance funding&nbsp;</li>
<li>Serum: Pricing for India remains at the lowest level possible at current supply&nbsp;</li>
<li>Serum: Cost of vaccine very low compared to covid&nbsp;treament&nbsp;across the nation&nbsp;</li>
<li>Adar Poonawalla: urge other vaccines to be imported into the market for pace of vaccination to rise&nbsp;</li>
</ul>

India's largest vaccine manufacturer Serum comes forward to clarify as it faces backlash on India paying the highest price for the Covishield vaccines. Serum in a statement released on Saturday said, that the comparison of global prices to Indian prices was inaccurate as the global vaccines were procured on advance funding.&nbsp; Serum also reassured&nbsp; that only a limited portion of it's total supply will be sold at Rs 600/dose as majority will be supplied at the govt procurement price of Rs 400/dose which as it states is much lower than any covid&nbsp;treatment plan in any health centre.&nbsp; Adar Ponawalla&nbsp;urged the market to opened up further for other vaccines from around the world to increase the vaccination pace.&nbsp;

Expect the current vaccine shortage to end in another 2-3 months as new supply comes on-stream, the Serum Chief Adar Poonawala told CNBC-TV18.&nbsp;
Ponawalla&nbsp;expects that 100 million doses will be ready by July end, out of which 50% will be given to the Central government and the rest to the private sector and the state governments.
Serum CEO&nbsp;also informed that they will start signing contracts with private hospitals for direct supply which would start by third or fourth week of May.&nbsp;
&nbsp;

Serum Chief says vaccine shortage will end in 2 months 

Adar Poonawalla&nbsp;expect the current vaccine shortage to end in another 2-3 months as new supply comes onstream and contracts with private centres kick-off

Expect the current vaccine shortage to end in another 2-3 months as new supply comes on-stream, the Serum Chief Adar Poonawala told CNBC-TV18.&nbsp;
Poonawalla&nbsp;expects that 100 million doses will be ready by July end, out of which 50% will be given to the Central government and the rest to the private sector and the state governments.
Serum CEO&nbsp;also informed that they will start signing contracts with private hospitals for direct supply which would start by third or fourth week of May.&nbsp;
&nbsp;

India may get a Covid-19 vaccine by March 2021: Serum

India may get a Covid-19 vaccine by March 2021, provided regulators give signals fast, says Serum India ED&nbsp;Dr Suresh Jadhav

India may get a Covid-19 vaccine by March 2021, provided regulators give signals fast, &ldquo;as multiple manufacturers are working on it&rdquo;, The Indian Express has reported quoting the executive director of the Serum Institute of India, which is testing the Oxford-AstraZeneca vaccine candidate in the country. Dr Suresh Jadhav told newspaper that India is heading fast towards vaccine development, as two manufacturers are already in phase-3 trial and one in the phase-2 trial, and more players are joining the race. He added that Serum will be ready with 60-70 million dosages of vaccines by December, but that will come in the market in 2021 after the clearance of licencing.

serum

Categories